Forskning
Udskriv Udskriv
Switch language
  1. Hvidovre Hospital
  2. Publikationer
  3. Magnesium sulphate treatment d...
  4. Citationsformater
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Harvard

Wolf, HT, Henriksen, TB, Larsen, ML, Pinborg, A, Hegaard, HK, Brok, JS & Huusom, LD 2020, 'Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth', Ugeskrift for Laeger, bind 182, nr. 47.

APA

Wolf, H. T., Henriksen, T. B., Larsen, M. L., Pinborg, A., Hegaard, H. K., Brok, J. S., & Huusom, L. D. (2020). Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth. Ugeskrift for Laeger, 182(47).

CBE

Wolf HT, Henriksen TB, Larsen ML, Pinborg A, Hegaard HK, Brok JS, Huusom LD. 2020. Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth. Ugeskrift for Laeger. 182(47).

MLA

Wolf, Hanne Trap o.a.. "Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth". Ugeskrift for Laeger. 2020. 182(47).

Vancouver

Wolf HT, Henriksen TB, Larsen ML, Pinborg A, Hegaard HK, Brok JS o.a. Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth. Ugeskrift for Laeger. 2020 nov. 16;182(47).

Author

Wolf, Hanne Trap ; Henriksen, Tine Brink ; Larsen, Mads Langager ; Pinborg, Anja ; Hegaard, Hanne Kristine ; Brok, Jesper Sune ; Huusom, Lene Drasbek. / Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth. I: Ugeskrift for Laeger. 2020 ; Bind 182, Nr. 47.

Bibtex

@article{03d5a8d96e0e4bf1bbc3369aaec3cd2b,
title = "Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth",
abstract = "Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.",
keywords = "Cerebral Palsy/prevention & control, Child, Female, Humans, Infant, Newborn, Magnesium Sulfate/therapeutic use, Neuroprotection, Neuroprotective Agents/therapeutic use, Pregnancy, Premature Birth/prevention & control, Prenatal Care, Randomized Controlled Trials as Topic",
author = "Wolf, {Hanne Trap} and Henriksen, {Tine Brink} and Larsen, {Mads Langager} and Anja Pinborg and Hegaard, {Hanne Kristine} and Brok, {Jesper Sune} and Huusom, {Lene Drasbek}",
year = "2020",
month = nov,
day = "16",
language = "English",
volume = "182",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "47",

}

RIS

TY - JOUR

T1 - Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

AU - Wolf, Hanne Trap

AU - Henriksen, Tine Brink

AU - Larsen, Mads Langager

AU - Pinborg, Anja

AU - Hegaard, Hanne Kristine

AU - Brok, Jesper Sune

AU - Huusom, Lene Drasbek

PY - 2020/11/16

Y1 - 2020/11/16

N2 - Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.

AB - Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.

KW - Cerebral Palsy/prevention & control

KW - Child

KW - Female

KW - Humans

KW - Infant, Newborn

KW - Magnesium Sulfate/therapeutic use

KW - Neuroprotection

KW - Neuroprotective Agents/therapeutic use

KW - Pregnancy

KW - Premature Birth/prevention & control

KW - Prenatal Care

KW - Randomized Controlled Trials as Topic

M3 - Journal article

C2 - 33215580

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 47

ER -

ID: 61730534